Literature DB >> 22760043

Performance of the Abbott RealTime HCV Genotype II RUO assay.

Rebecca C Shinol1, Howard B Gale, Virginia L Kan.   

Abstract

The Abbott RealTime HCV Genotype II RUO (research use only) assay was evaluated using the automated Abbott RealTime m2000 system. Concordance was 98% (81/83 samples) with samples previously typed by the Versant HCV Genotype 2.0 RUO system with manual extraction. The total assay time was reduced from 10.5 to 6.0 h and hands-on time from 13 to 4 min/patient sample.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22760043      PMCID： PMC3421783          DOI： 10.1128/JCM.01249-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Elevated prevalence of hepatitis C infection in users of United States veterans medical centers.

Authors:  Jason A Dominitz; Edward J Boyko; Thomas D Koepsell; Patrick J Heagerty; Charles Maynard; Jennifer L Sporleder; Andrew Stenhouse; Mitchel A Kling; William Hrushesky; Charles Zeilman; Stephen Sontag; Nikunj Shah; Fernando Ona; Bhupinder Anand; Marc Subik; Thomas F Imperiale; Samer Nakhle; Sam B Ho; Edmund J Bini; Bruce Lockhart; Jawad Ahmad; Anna Sasaki; Brian van der Linden; Doris Toro; Jaime Martinez-Souss; Vivek Huilgol; Seth Eisen; Keith A Young
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

2.  Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group.

Authors:  D B Smith; J Mellor; L M Jarvis; F Davidson; J Kolberg; M Urdea; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1995-07       Impact factor: 3.891

3.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

4.  Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors:  Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

5.  Telaprevir for retreatment of HCV infection.

Authors:  Stefan Zeuzem; Pietro Andreone; Stanislas Pol; Eric Lawitz; Moises Diago; Stuart Roberts; Roberto Focaccia; Zobair Younossi; Graham R Foster; Andrzej Horban; Peter Ferenci; Frederik Nevens; Beat Müllhaupt; Paul Pockros; Ruben Terg; Daniel Shouval; Bart van Hoek; Ola Weiland; Rolf Van Heeswijk; Sandra De Meyer; Don Luo; Griet Boogaerts; Ramon Polo; Gaston Picchio; Maria Beumont
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

6.  Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors:  Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

7.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

8.  Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.

Authors:  Helen S Yee; Michael F Chang; Christine Pocha; Joseph Lim; David Ross; Timothy R Morgan; Alexander Monto
Journal:  Am J Gastroenterol       Date:  2012-05       Impact factor: 10.864

9.  Performance evaluation of the Abbott RealTime HCV Genotype II for hepatitis C virus genotyping.

Authors:  Yong-Hak Sohn; Sun-Young Ko; Myeong Hee Kim; Heung-Bum Oh
Journal:  Clin Chem Lab Med       Date:  2010-04       Impact factor: 3.694

Review 10.  Natural history of hepatitis C infection: a concise review.

Authors:  J K Lim
Journal:  Yale J Biol Med       Date:  2001 Jul-Aug
View more
  3 in total

Review 1.  Hepatitis C virus: Virology, diagnosis and treatment.

Authors:  Hui-Chun Li; Shih-Yen Lo
Journal:  World J Hepatol       Date:  2015-06-08

Review 2.  Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.

Authors:  Verónica Saludes; Victoria González; Ramon Planas; Lurdes Matas; Vicente Ausina; Elisa Martró
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

3.  Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test.

Authors:  Camelia Mokhtari; Anne Ebel; Birgit Reinhardt; Sandra Merlin; Stéphanie Proust; Anne-Marie Roque-Afonso
Journal:  J Clin Microbiol       Date:  2015-11-18       Impact factor: 5.948
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.